MedTrace Logo

APX005M in Patients With Recurrent Ovarian Cancer

NCT05201001 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-09-11

No results posted yet for this study

Summary

The overall objective is to demonstrate preliminary efficacy of APX005M-carboplatin-PLD and APX005M-radiotherapy-carboplatin-PLD combinations as treatment for relapsed BRCAwt ovarian cancer patients, where platinum combination therapy is an option.

Conditions

Interventions

DRUG

APX005M

adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.

Sponsors & Collaborators

  • Belgian Gynaecological Oncology Group

    collaborator OTHER

  • GSO Global Clinical Research BV

    collaborator OTHER

  • The Central and Eastern European Gynecologic Oncology Group

    collaborator OTHER

  • Swiss GO Trial Group

    collaborator NETWORK

  • Nordic Society of Gynaecological Oncology - Clinical Trials Unit

    lead OTHER

Principal Investigators

  • Mansoor R Mirza · NSGO-CTU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-07
Primary Completion
2023-09-07
Completion
2023-09-07

Countries

  • Denmark

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05201001 on ClinicalTrials.gov